Cycle on Jul 28, 2026

I will list the open threads and watches for this topic to understand what we are tracking and what needs update or resolution.

I will search for recent news updates regarding the upcoming FDA Advisory Committee meetings for Capricor's deramiocel (scheduled for July 29, 2026) and Replimune's RP1 (late July 2026), as well as Saol Therapeutics' SL1009.

I will search for the Replimune RP1 FDA briefing documents and the latest news about its upcoming advisory committee meeting (since the headline mentions "FDA says Replimune's melanoma data package is 'not interpretable'"). I'll search with proper keywords.

I will now search for other watch items with upcoming deadlines in late July or early August 2026. Let's check Saol Therapeutics' SL1009 (DCA) resubmission acceptance / PDUFA date. (The watch says expected late July 2026). And let's also check Belite Bio's tinlarebant NDA acceptance. (Watch says expected early August 2026). And Moderna's mFlusiva (mRNA-1010) standard approval PDUFA target action date (August 5, 2026). Let's do a search for Saol Therapeutics SL1009.

This is excellent. We have a clear firing event for the watch on Saol Therapeutics' SL1009 (DCA) NDA resubmission. It was accepted with a PDUFA date of December 30, 2026. Let's fetch the actual press release for Saol's SL1009 resubmission acceptance to get precise details and quotes. Then we can record the event and write the finding. Let's do a fetch. I will check the URL. The URL is: `https://www.prnewswire.com/news-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026-302836586.html` or similar. Let's fetch it.

Excellent. Now let's search for other upcoming watch deadlines. What about MoonLake's Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis (PsA)? The watch says expected mid-2026. Let's do a search for MoonLake sonelokimab.

Excellent. The MoonLake sonelokimab psoriatic arthritis topline Phase 3 IZAR program readout (IZAR-1 study) is expected in the third and fourth quarters of 2026 (according to the Leerink note: "catalysts ahead, including topline Phase 3 IZAR program readouts in psoriatic arthritis in the third and fourth quarters of 2026"). So that watch is still forward-looking and has not fired yet. Let's check another watch: "Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN" expected in Q3 2026. Let's do a search for Vera ORIGIN eGFR confirmatory results.

This is a massive regulatory development. On July 7, 2026, Vera Therapeutics received FDA accelerated approval for TRUTAKNA™ (atacicept) to reduce proteinuria in adult patients with primary IgA nephropathy (IgAN). Continued approval is contingent upon the ORIGIN 3 confirmatory eGFR results, expected in Q3 2026. Wait, let's look at the Otsuka sibeprenlimab (VOYXACT) news: "Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)" on July 1, 2026. This is also major kidney disease news. Let's do some more searches on other watch items, like the FDA response to the citizen petition trying to halt CRL public disclosure (expected around October 2026). Let's search Docket No. FDA-2026-P-4369. Or let's check: "FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma" -> This meeting is scheduled for Thursday, July 30, 2026. We saw the briefing docs just came out today (July 28, 2026) and staff reviews are extremely critical, calling the data package "not interpretable". And "FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy" -> Briefing documents released Monday morning, July 27, 2026, ahead of the Wednesday, July 29, 2026 Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting. The FDA reviewers disagreed with Capricor's Phase 3 success claims, saying the trial did "not meet its pre-specified primary and secondary efficacy endpoints" and that Capricor changed the statistical analysis plan post-hoc several times. This is incredibly negative for deramiocel's approval prospects and caused a 65% stock plunge. Let's check if there are updates on other watch items: 1. uniQure's AMT-130 in Huntington's disease BLA submission (expected Q3 2026). Let's search for uniQure AMT-130. 2. Omeros's narsoplimab TA-TMA EMA re-examination. Let's search Omeros narsoplimab EMA. 3. Sobi BLA resubmission for NASP (nanoencapsulated sirolimus plus pegadricase) in uncontrolled gout. Let's search Sobi NASP. 4. Achieve Life Sciences cytisinicline smoking cessation NDA resubmission. Let's search Achieve cytisinicline. Let's run a search for uniQure AMT-130 and Omeros.

Let's split the search terms to get results for each biotech company individually. First: "uniQure" "AMT-130" Huntington's disease BLA or FDA or clinical trial.

This is incredible. Let's analyze what happened here: 1. "uniQure's HD Therapy Gets Fast Track to FDA Filing": "FDA accepts three-year AMT-130 data as basis for accelerated approval, putting uniQure on track to file in Q3." Wait, what is this "FDA reversed course" about? "Weeks later, however, the FDA reversed course on previous guidance, telling uniQure it 'no longer agree[d]' that data from the Phase 1/2 trial would be 'adequate to provide the primary evidence in support of a BLA submission.' Instead, the FDA insisted on a sham surgery–controlled Phase 3 study. But after both men departed the agency this spring, the FDA reversed course and agreed that uniQure’s existing data would be sufficient to support an accelerated application for AMT-130." Ah! There is a massive storyline here: - Initially, the FDA told uniQure they could file on Phase 1/2 data. - Then, the FDA reversed course and said they need a Phase 3 trial. - Then, this spring, after leadership changes at the FDA, the FDA reversed course *again* ("agreed that uniQure’s existing data would be sufficient to support an accelerated application for AMT-130"), allowing uniQure to file for accelerated approval based on the three-year AMT-130 data. They are currently on track to file the BLA in Q3 2026. This is a very important update to the uniQure watch! Let's search for Omeros narsoplimab EMA re-examination.

Great, so the Omeros narsoplimab negative CHMP opinion happened on June 26, 2026. OmerosIreland plans to request a re-examination and seek assessment by an Ad Hoc Expert Panel. Let's check other watch items: "Sobi BLA resubmission for NASP (nanoencapsulated sirolimus plus pegadricase) in uncontrolled gout" -> Let's search for Sobi NASP. "Achieve Life Sciences' planned NDA resubmission in Q4 2026 for cytisinicline in smoking cessation" -> Let's search for Achieve cytisinicline. "GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP" -> Let's search GondolaBio PATHWAY PORT-77. "Amgen Tavneos EMA revocation or NEJM retraction" -> Wait, we have prior findings on Amgen Tavneos: "Amgen's Tavneos Faces Retraction and EMA Revocation Ahead of Critical FDA Hearing Deadline" (slug: `amgen-tavneos-retraction-ema-revocation-hearing-deadline`). Let's search for recent updates on Amgen Tavneos. Let's see if there are any updates in the last month on Amgen Tavneos. Let's search for Sobi NASP, Achieve cytisinicline, GondolaBio, and Amgen Tavneos.

Let's separate those search terms. First: "Sobi" "NASP" or "sirolimus" pegadricase. Let's do a broader search.

Ah, the search budget is spent. That is perfectly fine, we have gathered a wealth of fresh, high-salience, concrete evidence on several of our most important watches and topics. Let's review the findings and updates we need to write: 1. **Capricor's deramiocel in DMD cardiomyopathy:** - On July 27, 2026, the FDA released its briefing documents ahead of the Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting scheduled for July 29, 2026. - The FDA staff reviewers strongly disagreed with Capricor's Phase 3 success claims, stating that the HOPE-3 trial did "not meet its pre-specified primary and secondary efficacy endpoints" and showing "no statistically significant difference between deramiocel and placebo at 12 months." - The FDA raised serious concerns about post-hoc modifications to the statistical analysis plan (SAP), noting that changes were made *after* the randomized, double-blind part of the trial was completed and during the open-label extension. - The FDA also flagged issues with blinding due to the distinctive adverse event profile (hypersensitivity reactions in 42% of deramiocel patients vs 15% of placebo). - In response, Capricor's stock plummeted by over 65% to $6.53. Capricor's CEO Linda Marbán defended the results, arguing that the FDA used an obsolete draft (SAP version 1.1) rather than the finalized SAP version 3.0. - We will write an updated note for this topic, reusing the slug: `amgen-tavneos-regulatory-crisis-advocate-retraction`? No, wait! What is the slug for Capricor's deramiocel? Wait, let's look at the kickoff message's prior findings: - `hhs-clinical-trials-reform-operation-trailblazer` - `fda-crl-public-disclosure-policy` - `amgen-tavneos-retraction-ema-revocation-hearing-deadline` - `amgen-tavneos-regulatory-crisis-advocate-retraction` Ah, there is no prior finding for Capricor's deramiocel in the prior findings list! So we will write a fresh note for it. Let's name the slug: `capricor-deramiocel-dmd-fda-advisory-committee` or `capricor-deramiocel-regulatory-crisis-dmd`. Let's use `capricor-deramiocel-regulatory-crisis-dmd`. Wait, let's check if there is an existing watch on deramiocel. Yes! - Watch ID: `019f061f-f34a-7079-a276-d216329928b2`, title: `FDA advisory committee meeting for Capricor's deramiocel in DMD cardiomyopathy`. This watch is a `one_shot` watch. Since the briefing documents have hit and the meeting is happening tomorrow (July 29, 2026), we can record that this watch has fired (or we can record it when the final vote/discussion happens, but since the briefing docs have been released and the debate is live, we can record the event now or keep it open until the vote results are out. Let's record the event as resolving false or true? It resolves: true because the briefing docs and the meeting are happening on July 29, 2026. Wait! Let's resolve it after the meeting or record the event now. Let's record the event now as it represents the major catalyst). 2. **Replimune's RP1 (Tudriqev) in advanced melanoma:** - On July 28, 2026, the FDA released briefing documents ahead of the CTGTAC meeting on July 30, 2026. - The FDA staff reviewers called Replimune's single-arm Phase 2 IGNYTE study "not interpretable" and stated that it was not "an adequate and well-controlled clinical investigation that demonstrates substantial evidence of effectiveness." - The FDA specifically targeted the lack of a randomized comparator arm, arguing that the overall survival and efficacy results remain unclear. - Replimune countered in its own briefing document that a randomized trial comparing RP1 + nivolumab to nivolumab monotherapy in patients whose cancers had already progressed on anti-PD-1 therapy was "not feasible or ethical" because anti-PD-1 monotherapy offers "no hope for response" or clinical benefit in this population. - Following this, Replimune's shares dropped by over 31% on July 28, 2026. - We will write a fresh note on this. Let's name the slug: `replimune-rp1-melanoma-fda-advisory-committee`. - Watch ID: `019f0620-007b-7dab-87b4-0363a2496ea1` is `FDA advisory committee meeting and PDUFA date for Replimune's RP1 in advanced melanoma`. The advisory committee meeting is on July 30, 2026, and the PDUFA date is August 2, 2026. We can record the event that the briefing docs have hit and the adcomm is set up, or keep it open. 3. **Saol Therapeutics' SL1009 (sodium dichloroacetate / DCA):** - On July 28, 2026, Saol Therapeutics announced that the FDA accepted its resubmitted NDA for SL1009 to treat Pyruvate Dehydrogenase Complex Deficiency (PDCD). - The FDA confirmed the resubmission is complete, classified it as Class 2, and assigned a PDUFA target action date of December 30, 2026. - The resubmission addresses the August 27, 2025 Complete Response Letter (CRL), which did not identify safety or manufacturing concerns but requested additional survival analyses. Saol conducted these analyses following Type A and Type C meetings. - Watch ID: `019f67f8-1a98-7a61-a210-07071f61b308` is `FDA filing acceptance and PDUFA date for Saol's SL1009`. This watch has fired! We will record the event and resolve this thread. - Let's write a note on this. Let's name the slug: `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance`. 4. **Vera Therapeutics' TRUTAKNA™ (atacicept):** - On July 7, 2026, the FDA granted accelerated approval to Vera Therapeutics' TRUTAKNA™ (atacicept) for reducing proteinuria in adult patients with primary IgA nephropathy (IgAN) at risk of disease progression. - TRUTAKNA is the first BAFF/APRIL dual inhibitor approved for IgAN. The approval was supported by Phase 3 ORIGIN 3 trial data, where patients achieved a 46% reduction in proteinuria at 36 weeks. - Continued approval may be contingent upon verification of clinical benefit (measured by estimated glomerular filtration rate, or eGFR) in the ongoing ORIGIN 3 trial, with results expected in Q3 2026. - This sets up a major market battle in IgAN against Novartis's Fabhalta and Otsuka's VOYXACT® (sibeprenlimab), the latter of which just reported positive Phase 3 VISIONARY two-year eGFR results on July 1, 2026. - Let's write a note on this. Let's name the slug: `vera-therapeutics-trutakna-fda-approval-igan`. - Watch ID: `019f3ec3-9518-7baa-a4e4-19e437e0557f` is `Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN`. This watch is still pending (results expected in Q3 2026), so we will keep it open. 5. **uniQure's AMT-130 in Huntington's disease:** - The BLA path has been dramatically cleared. After previously telling uniQure that Phase 1/2 data would not support a BLA (reversing previous guidance and demanding a Phase 3 sham-controlled trial), the FDA reversed course *again* this spring following leadership changes. - The FDA agreed that existing data from the Phase 1/2 trial would be sufficient to support an accelerated approval BLA for AMT-130. - uniQure has aligned with the FDA on the primary statistical analysis plan and CMC requirements, and is on track to submit the BLA in Q3 2026. - Let's write a note on this. Let's name the slug: `uniqure-amt130-huntingtons-disease-regulatory-path`. - Watch ID: `019ed7c8-8ce2-7ba0-9576-f823526d0677` is `uniQure BLA submission for AMT-130 in Huntington's disease`. This watch is still pending (submission expected in Q3 2026), so we will keep it open. Wait! Let's check the watch on Omeros: - Watch ID: `019f0620-addd-7ac7-9db1-1ce428418522` is `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA`. Since the CHMP issued a negative opinion on June 26, 2026, and Omeros announced its intention to request a re-examination, this watch is still active (the re-examination process is ongoing). We can write a finding about this development under a new note or update an existing one. Let's see if we should write a note. Let's name the slug: `omeros-narsoplimab-ema-regulatory-setback`. Let's write these notes one by one. First, let's record the event for Saol Therapeutics' SL1009 watch. Watch ID: `019f67f8-1a98-7a61-a210-07071f61b308`. Let's call `record_event`.I will record that the watch for Saol Therapeutics' SL1009 NDA resubmission acceptance and PDUFA date has successfully fired, resolving this one-shot watch.

Great. Now I will write the finding for Saol Therapeutics' SL1009 resubmission acceptance. Let's name the slug: `saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance`. Let's draft the body carefully, making sure we carry the evidence forward with exact quotes and links. Let's double-check the details of Saol's SL1009 (DCA): - PR Newswire URL: `https://www.prnewswire.com/news-releases/saol-therapeutics-announces-the-acceptance-of-resubmission-of-sl1009-dca-by-the-fda-with-pdufa-date-of-dec-30-2026-302836586.html` - Date: July 28, 2026. - Quotes: - "The FDA acknowledged the resubmission as complete, classified it as Class 2, and set a Prescription Drug User Fee Act (PDUFA) target action date of Dec. 30, 2026." - "Having a confirmed action date matters greatly to the families of children living with PDCD, who have waited a long time for a potential treatment option" (Dave Penake, CEO). - SL1009 received Priority Review, Orphan Drug Designation, and Rare Pediatric Disease Designation. Saol anticipates receiving a PRV. - Saol, in collaboration with Medosome Biotec, will file a 510K for the dose-determining genetic test companion diagnostic. Let's write this note.I will write a research note detailing the FDA's acceptance of Saol Therapeutics' resubmitted NDA for SL1009 (sodium dichloroacetate) to treat Pyruvate Dehydrogenase Complex Deficiency, setting a PDUFA date of December 30, 2026.

Fantastic. Now let's write the note for **Capricor's deramiocel regulatory crisis**. Let's name the slug: `capricor-deramiocel-regulatory-crisis-dmd`. Let's review the details of the Capricor deramiocel FDA briefing docs: - Briefing documents released on Monday morning, July 27, 2026. - CTGTAC meeting scheduled for Wednesday, July 29, 2026. - The FDA staff reviewers noted that the HOPE-3 trial did "not meet its pre-specified primary and secondary efficacy endpoints, showing no statistically significant difference between deramiocel and placebo at 12 months." - The FDA noted post-hoc changes to the pre-specified statistical analysis plan (SAP), generating at least two additional versions (specifically version 1.1 vs version 3.0), modifying primary/secondary endpoints, analytical methods, and data imputation. - Blinding concerns were raised due to hypersensitivity reactions in 42% of deramiocel patients vs 15% of placebo. - Capricor CEO Linda Marbán said in an interview: - "It's been very disconcerting to us. We take great issue with how FDA analyzed the data using [SAP version 1.1]." - "So we were blown away that they would use something that was not even intended by us ever to be used." - "I fundamentally believe that the adcomm will be able to see through the statistical analysis plans and not turn this into something mathematical, but actually look at the treatment effect that has been consistent [across Capricor's trials]." - "Our results are governed by the final analysis plan, SAP version 3.0, which was finalized prior to unblinding." Let's write this note.I will write a research note detailing the regulatory and clinical integrity crisis facing Capricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy cardiomyopathy, following the release of highly critical FDA briefing documents.

Excellent. Now let's write the note for **Replimune's RP1 (Tudriqev) FDA briefing documents and adcomm**. Let's name the slug: `replimune-rp1-melanoma-fda-advisory-committee`. Let's review the details of the Replimune RP1 briefing: - FDA briefing documents released on Tuesday, July 28, 2026, ahead of the CTGTAC meeting on Thursday, July 30, 2026. - The FDA staff reviewers noted that the Phase 2 single-arm IGNYTE study—which Replimune relies on to support accelerated approval of RP1 in combination with Opdivo (nivolumab) in advanced cutaneous melanoma—was not "an adequate and well-controlled clinical investigation that demonstrates substantial evidence of effectiveness." - Specifically, the FDA wrote: "The overall survival analysis from the single-arm IGNYTE study is not interpretable." - Replimune argued in its own briefing document: - "It is not feasible or ethical to randomize this patient population to a comparator arm of anti-PD-1 monotherapy that offered no hope for response, therefore a study comparing RP1 in combination with nivolumab, to nivolumab monotherapy in patients whose disease progressed while on nivolumab or other anti-PD-1 was not conducted." - Replimune's shares dropped by nearly 31% on Tuesday, July 28, 2026. - The advisory committee will vote on just one question on Thursday: "Are the efficacy results from IGNYTE evaluable and clinically meaningful?" Let's write this note.I will write a research note detailing the FDA's critical briefing documents on Replimune's skin cancer drug RP1, highlighting the single-arm trial design controversy.

Excellent. Now let's write the note for **Vera Therapeutics' TRUTAKNA™ (atacicept) FDA Accelerated Approval**. Let's name the slug: `vera-therapeutics-trutakna-fda-approval-igan`. Let's review the details of the Vera TRUTAKNA approval: - On July 7, 2026, the FDA granted accelerated approval to TRUTAKNA™ (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of disease progression. - TRUTAKNA is a BAFF and APRIL dual inhibitor, the first of its kind approved for IgAN. BAFF and APRIL target upstream pathogenic drivers of IgAN, specifically suppressing galactose-deficient IgA1 (Gd-IgA1) levels. - The approval is supported by Phase 3 ORIGIN 3 trial data, where patients achieved a 46% reduction in proteinuria from baseline at 36 weeks (or a 42% reduction compared to placebo, with a 68% lowering of Gd-IgA1). - Continued approval is contingent upon verification and description of clinical benefit in the ongoing ORIGIN 3 trial, which evaluates estimated glomerular filtration rate (eGFR) over two years, with results anticipated in Q3 2026. - This creates a major market battle. Novartis's Fabhalta is already approved, and Otsuka reported positive Phase 3 VISIONARY two-year eGFR results for VOYXACT® (sibeprenlimab-szsi) on July 1, 2026, which demonstrated it prevented progression to kidney failure and improved kidney function. Let's write this note.I will write a research note detailing the FDA's accelerated approval of Vera Therapeutics' TRUTAKNA (atacicept) for primary IgA nephropathy, setting up a competitive landscape in the autoimmune kidney disease market.

Excellent. Now let's write the note for **uniQure's AMT-130 in Huntington's disease BLA pathway**. Let's name the slug: `uniqure-amt130-huntingtons-disease-regulatory-path`. Let's review the details of uniQure's AMT-130 BLA path: - A single dose of uniQure's gene therapy AMT-130 slowed disease progression by 75% after three years on the cUHDRS scale compared to matched external controls. - The FDA previously told uniQure it "no longer agree[d]" that Phase 1/2 data would support a BLA, insisting on a sham surgery-controlled Phase 3 study. - However, this spring, after leadership changes at the FDA, the FDA reversed course *again* ("agreed that uniQure’s existing data would be sufficient to support an accelerated application for AMT-130"). - uniQure has now achieved alignment with the FDA on key components of the primary statistical analysis plan and CMC requirements for AMT-130. - uniQure is on track to submit the BLA for accelerated approval of AMT-130 in Huntington's disease in Q3 2026. - This represents a massive win for uniQure and Huntington's disease patients, clearing major regulatory hurdles. Let's write this note.I will write a research note detailing the FDA's regulatory reversal that put uniQure's Huntington's disease gene therapy AMT-130 back on track for a BLA submission in Q3 2026.

Excellent. Now let's write a note on **Omeros's narsoplimab EMA regulatory setback**. Let's name the slug: `omeros-narsoplimab-ema-regulatory-setback`. Let's review the details of Omeros's narsoplimab EMA setback: - On June 26, 2026, Omeros announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the marketing authorization application (MAA) for narsoplimab (to be marketed as Yartemlea) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). - Following an oral explanation meeting where Omeros presented its position with four international experts in hematopoietic cell transplantation, the CHMP issued a negative opinion. - Omeros plans to request a re-examination of the opinion and seek assessment by an Ad Hoc Expert Panel, an independent group of external clinical and scientific specialists assembled by the EMA. - Narsoplimab was previously approved by the FDA in December 2025 as the first and only approved treatment for TA-TMA in adults and pediatric patients aged two years and older. - The European setback introduces significant uncertainty for Omeros, as the company's operating profile relies on narsoplimab's commercial ramp to avoid a dilutive financing event. Let's write this note.I will write a research note detailing the EMA CHMP's negative opinion on Omeros's narsoplimab for TA-TMA and the company's plans for re-examination.

Excellent. Now let's review the active threads and if we can resolve any. Let's see if we can resolve the thread for Saol Therapeutics SL1009 resubmission acceptance: Thread ID: `019f67f8-1a98-7a61-a210-07071f61b308`. Yes! We recorded the event and wrote the note. Let's resolve this thread.I will resolve the thread regarding Saol Therapeutics' SL1009 resubmission acceptance, as this cycle has confirmed the FDA's acceptance and PDUFA date assignment.

Great. Now let's register any new watches or threads if appropriate. Wait, let's look at the other watches. Are there any other watches we should register based on forward-looking catalysts? - We have a watch on Capricor's deramiocel CTGTAC adcomm, but the PDUFA date or final FDA decision on deramiocel BLA is still upcoming. Let's see if we should register a watch for the FDA's final regulatory decision on Capricor's deramiocel BLA. The action date is expected around late August or September 2026. Let's register a watch for this. - We have a watch on Replimune's RP1 CTGTAC adcomm and PDUFA date. (PDUFA date is August 2, 2026). Let's keep that watch open or register a separate watch for the FDA's final decision on Replimune's RP1. Since we already have `019f0620-007b-7dab-87b4-0363a2496ea1` which covers both the adcomm and the PDUFA date, we can keep it open. - We have a watch on Saol Therapeutics' SL1009 PDUFA date. Oh, wait! The watch `019f67f8-1a98-7a61-a210-07071f61b308` was for the "FDA filing acceptance and PDUFA date for Saol's SL1009", which we just resolved. We should register a new watch for the FDA's final regulatory decision on SL1009 on its PDUFA date, December 30, 2026. Let's call `record_watch` for Saol's PDUFA date on December 30, 2026.I will register a new watch for the FDA's final regulatory decision on Saol Therapeutics' SL1009 for PDCD, expected on its PDUFA date of December 30, 2026.

Great. Now let's register a watch for the FDA's final regulatory decision on Capricor's deramiocel BLA. The action date is expected around late August or September 2026. Let's register it.I will register a new watch for the FDA's final regulatory decision on Capricor Therapeutics' deramiocel BLA for DMD cardiomyopathy, which is expected by late August or September 2026.

Excellent. We have covered all bases. Let's call `finish_cycle` to complete this research cycle successfully. Wait, let's make sure we don't pass `no_findings_reason` since we wrote several findings this cycle. We will leave it empty. Let's call `finish_cycle`.I will now call finish_cycle to end the research cycle, having written several findings and registered/resolved the relevant watches and threads.

This research cycle has been successfully completed. Here is a summary of the findings and updates recorded during this cycle: ### 1. **Capricor's Deramiocel Faces FDA Staff Disagreement Ahead of CTGTAC Meeting** * **Finding:** `[[capricor-deramiocel-regulatory-crisis-dmd]]` * **Summary:** The FDA released highly critical briefing documents on July 27, 2026, ahead of the July 29 CTGTAC advisory committee meeting for Capricor's deramiocel cell therapy in DMD cardiomyopathy. Reviewers stated that the HOPE-3 trial did not meet its pre-specified primary/secondary endpoints, noted post-hoc statistical analysis plan modifications, and raised concerns about the trial's blinding due to a distinct AE profile (42% hypersensitivity in treatment vs 15% in placebo). Capricor's stock plunged over 65% in response. * **Watch Registered:** `FDA final regulatory decision on Capricor's deramiocel BLA in DMD cardiomyopathy` (Target: August/September 2026). ### 2. **Replimune's Skin Cancer Immunotherapy RP1 Deemed "Not Interpretable" by FDA Staff** * **Finding:** `[[replimune-rp1-melanoma-fda-advisory-committee]]` * **Summary:** On July 28, 2026, the FDA staff released briefing documents ahead of the July 30 CTGTAC meeting, calling Replimune's single-arm Phase II IGNYTE study "not interpretable" due to the lack of a randomized comparator arm. Replimune defended its design on ethical grounds, arguing that randomizing patients who had already progressed on anti-PD-1 therapy to anti-PD-1 monotherapy would offer no hope of clinical benefit. Replimune shares plummeted nearly 31%. ### 3. **Saol Therapeutics' SL1009 NDA Resubmission Accepted with December 2026 PDUFA Date** * **Finding:** `[[saol-therapeutics-sl1009-mitochondrial-disease-fda-acceptance]]` * **Summary:** Saol announced on July 28, 2026, that the FDA accepted its resubmitted NDA for SL1009 (sodium dichloroacetate) for the treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD). The FDA classified it as a complete Class 2 response and assigned a PDUFA date of December 30, 2026. * **Watch Resolved:** `FDA filing acceptance and PDUFA date for Saol's SL1009` (Resolved). * **Watch Registered:** `FDA final regulatory decision on Saol's SL1009 (DCA) in PDCD` (Target: December 30, 2026). ### 4. **Vera Therapeutics' TRUTAKNA™ (atacicept) Wins Accelerated FDA Approval** * **Finding:** `[[vera-therapeutics-trutakna-fda-approval-igan]]` * **Summary:** On July 7, 2026, the FDA granted accelerated approval to Vera's TRUTAKNA™, a BAFF/APRIL dual inhibitor, to reduce proteinuria in adults with primary IgA nephropathy (IgAN). The approval was supported by Phase 3 ORIGIN 3 data showing a 46% proteinuria reduction and 68% Gd-IgA1 suppression at 36 weeks. Continued approval is contingent upon verification of eGFR clinical benefit in the ongoing ORIGIN 3 trial, with results expected in Q3 2026, setting up a major market battle against Novartis's Fabhalta and Otsuka's VOYXACT® (which reported positive Phase 3 VISIONARY results on July 1, 2026). ### 5. **uniQure's Huntington's Disease Gene Therapy AMT-130 Cleared for Q3 2026 BLA Filing** * **Finding:** `[[uniqure-amt130-huntingtons-disease-regulatory-path]]` * **Summary:** Following multiple regulatory reversals, the FDA agreed this spring that uniQure's existing Phase 1/2 data (supported by 3-year follow-up showing a 75% slowing of disease progression) is sufficient to support a BLA for accelerated approval. uniQure has aligned with the FDA on statistical plans and CMC requirements and is on track to file the BLA in Q3 2026. ### 6. **Omeros Ireland Faces European Regulatory Setback on Narsoplimab** * **Finding:** `[[omeros-narsoplimab-ema-regulatory-setback]]` * **Summary:** On June 26, 2026, the EMA's CHMP adopted a negative opinion on the MAA for narsoplimab (Yartemlea) in TA-TMA, diverging from its December 2025 FDA approval. Omeros plans to request a formal re-examination and seek assessment by an independent Ad Hoc Expert Group. This setback introduces cash-runway uncertainties for the company.